Quest Diagnostics
About: Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Employees: 56,000
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
300% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 4 (+3) [Q2]
45% more first-time investments, than exits
New positions opened: 119 | Existing positions closed: 82
11% more capital invested
Capital invested by funds: $17.2B [Q1] → $19.1B (+$1.94B) [Q2]
3.87% more ownership
Funds ownership: 91.67% [Q1] → 95.55% (+3.87%) [Q2]
1% more funds holding
Funds holding: 948 [Q1] → 960 (+12) [Q2]
9% more repeat investments, than reductions
Existing positions increased: 352 | Existing positions reduced: 322
36% less call options, than puts
Call options by funds: $58.9M | Put options by funds: $92.6M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$178
0%
upside
Avg. target
$186
4%
upside
High target
$194
9%
upside
4 analyst ratings
0 positive
0%
4 neutral
100%
0 negative
0%
Baird Eric Coldwell | 9%upside $194 | Neutral Downgraded | 25 Aug 2025 |
UBS Kevin Caliendo | 1%upside $180 | Neutral Maintained | 23 Jul 2025 |
Truist Securities David Macdonald | 7%upside $192 | Hold Maintained | 23 Jul 2025 |
Deutsche Bank Pito Chickering | 0%downside $178 | Hold Maintained | 23 Jul 2025 |
Financial journalist opinion
Based on 10 articles about DGX published over the past 30 days
Neutral
PRNewsWire
1 day ago
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
SECAUCUS, N.J. , Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.
Positive
Zacks Investment Research
4 days ago
Why Is Quest Diagnostics (DGX) Up 8.2% Since Last Earnings Report?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Negative
Zacks Investment Research
4 days ago
Should Quest Diagnostics Stock Be in Your Portfolio Right Now?
DGX drives growth with advanced diagnostics, acquisitions and cost savings, but rising debt and macro risks weigh on its outlook.
Neutral
PRNewsWire
1 week ago
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference
SECAUCUS, N.J. , Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2025 Global Healthcare Conference in New York City on Wednesday, September 10, 2025, at 10:50 a.m.
Positive
Zacks Investment Research
1 week ago
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Neutral
PRNewsWire
1 week ago
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest Diagnostics common stock on October 3, 2025.
Neutral
PRNewsWire
2 weeks ago
Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
SECAUCUS, N.J. and BOSTON , Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology.
Neutral
PRNewsWire
3 weeks ago
Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care
SECAUCUS, N.J. , Aug. 5, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its previously announced acquisition of select clinical testing assets of Fresenius Medical Care's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the United States.
Neutral
PRNewsWire
4 weeks ago
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON , July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxia, a group of progressive, degenerative neurological disorders that affect movement or coordination. The new service is a laboratory developed test that identifies sequences of DNA that repeat many times across a long stretch of the genome.
Positive
Zacks Investment Research
4 weeks ago
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Charts implemented using Lightweight Charts™